ZA200905306B - Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity - Google Patents
Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivityInfo
- Publication number
- ZA200905306B ZA200905306B ZA200905306A ZA200905306A ZA200905306B ZA 200905306 B ZA200905306 B ZA 200905306B ZA 200905306 A ZA200905306 A ZA 200905306A ZA 200905306 A ZA200905306 A ZA 200905306A ZA 200905306 B ZA200905306 B ZA 200905306B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- urinary tract
- overactive bladder
- lower urinary
- tract symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07103483A EP1967202A1 (fr) | 2007-03-05 | 2007-03-05 | Utilisation d'antagonistes LHTH pour le traitement des symptômes de tractus urinaires faibles, en particulier la vessie hyperactive et/ou hyperactivité du détrusor |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200905306B true ZA200905306B (en) | 2010-04-28 |
Family
ID=38006763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200905306A ZA200905306B (en) | 2007-03-05 | 2009-07-30 | Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090075937A1 (fr) |
EP (2) | EP1967202A1 (fr) |
JP (1) | JP2010520257A (fr) |
KR (1) | KR20100014923A (fr) |
CN (1) | CN101657211A (fr) |
AU (1) | AU2008223841A1 (fr) |
BR (1) | BRPI0808488A2 (fr) |
CA (1) | CA2679690A1 (fr) |
IL (1) | IL200182A0 (fr) |
MX (1) | MX2009009320A (fr) |
RU (1) | RU2009136642A (fr) |
WO (1) | WO2008107446A1 (fr) |
ZA (1) | ZA200905306B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2704298C (fr) | 2007-11-02 | 2015-07-21 | Astellas Pharma Inc. | Composition pharmaceutique pour traiter une vessie hyperactive |
TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以GnRH拮抗劑治療攝護腺癌的方法 |
EP2095818A1 (fr) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Utilisation d'antagonistes LHRH dans des doses n'impliquant pas de castration |
US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
EP2424503B1 (fr) | 2009-05-01 | 2017-07-05 | Ferring BV | Composition pour le traitement du cancer de la prostate |
EP2266567A1 (fr) * | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel |
EP2266568A1 (fr) * | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel |
US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
KR20130135239A (ko) * | 2010-08-03 | 2013-12-10 | 앨씨알엑스, 인크. | 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제 |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
PL2632934T3 (pl) | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
EP2447276A1 (fr) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Procédé pour la fabrication du degarelix et de ses intermédiaires |
JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
BR112015005351A2 (pt) | 2012-09-18 | 2017-07-04 | Taris Biomedical Llc | sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior |
US9956194B2 (en) | 2014-12-03 | 2018-05-01 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
PT3365321T (pt) | 2015-10-23 | 2024-01-12 | B3Ar Therapeutics Inc | Zwiterião de solabegron e suas utilizações |
BR112021001337A2 (pt) | 2018-08-01 | 2021-04-20 | Taris Biomedical Llc | métodos de tratamento de bexiga hiperativa usando tróspio |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
NZ536787A (en) * | 1998-06-11 | 2006-03-31 | Endorech Inc | Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol |
AU2001295359A1 (en) * | 2000-10-30 | 2002-05-15 | University Of Zurich | GnRH analogues for treatment of urinary incontinence |
RU2319692C2 (ru) * | 2001-12-14 | 2008-03-20 | Центарис Гмбх | Производные тетрагидрокарбазола, способ получения производных тетрагидрокарбазола (варианты), их применение (варианты) и фармацевтическая композиция, обладающая активностью антагониста гонадотропин-рилизинг-гормона (варианты) |
DE10164564B4 (de) * | 2001-12-14 | 2007-05-16 | Zentaris Gmbh | Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR) |
GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
DE102004033902A1 (de) * | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
-
2007
- 2007-03-05 EP EP07103483A patent/EP1967202A1/fr not_active Withdrawn
-
2008
- 2008-03-05 MX MX2009009320A patent/MX2009009320A/es not_active Application Discontinuation
- 2008-03-05 EP EP08709284A patent/EP2131854A1/fr not_active Withdrawn
- 2008-03-05 JP JP2009552194A patent/JP2010520257A/ja active Pending
- 2008-03-05 CN CN200880007201A patent/CN101657211A/zh active Pending
- 2008-03-05 BR BRPI0808488-2A patent/BRPI0808488A2/pt not_active IP Right Cessation
- 2008-03-05 WO PCT/EP2008/052640 patent/WO2008107446A1/fr active Application Filing
- 2008-03-05 CA CA002679690A patent/CA2679690A1/fr not_active Abandoned
- 2008-03-05 AU AU2008223841A patent/AU2008223841A1/en not_active Abandoned
- 2008-03-05 KR KR1020097018620A patent/KR20100014923A/ko not_active Application Discontinuation
- 2008-03-05 RU RU2009136642/15A patent/RU2009136642A/ru not_active Application Discontinuation
- 2008-03-05 US US12/042,522 patent/US20090075937A1/en not_active Abandoned
-
2009
- 2009-07-30 ZA ZA200905306A patent/ZA200905306B/xx unknown
- 2009-07-30 IL IL200182A patent/IL200182A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20090075937A1 (en) | 2009-03-19 |
IL200182A0 (en) | 2010-04-15 |
EP1967202A1 (fr) | 2008-09-10 |
MX2009009320A (es) | 2009-09-10 |
EP2131854A1 (fr) | 2009-12-16 |
CN101657211A (zh) | 2010-02-24 |
AU2008223841A1 (en) | 2008-09-12 |
JP2010520257A (ja) | 2010-06-10 |
RU2009136642A (ru) | 2011-04-10 |
WO2008107446A1 (fr) | 2008-09-12 |
BRPI0808488A2 (pt) | 2014-07-15 |
KR20100014923A (ko) | 2010-02-11 |
CA2679690A1 (fr) | 2008-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL200182A0 (en) | Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity | |
AP2011005672A0 (en) | Pyrazolopyrimidines and their use for the treatment of CNS disorders. | |
EP2087094A4 (fr) | Lactobacillus fermentum ess-1, dsm17851 et son utilisation pour le traitement et/ou la prévention de la candidose et des infections des voies urinaires | |
PT2162118T (pt) | Microesferas porosas e sua utilização em terapia | |
IL199045A0 (en) | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases | |
PL1912650T3 (pl) | Zastosowanie flibanseryny w leczeniu otyłości | |
IL181369A0 (en) | Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder | |
HK1215683A1 (zh) | 抗葉酸藥在癌症治療中的聯合應用 | |
IL202674A0 (en) | Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma | |
IL198461A (en) | 3 alpha androstandiol and type 5 phosphodiesterase inhibitor (pde5 for on-demand use in the treatment of sexual dysfunction | |
IL215583A0 (en) | Methods for preventing and/or treating lysosomal storage disorders | |
WO2009024667A3 (fr) | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan | |
IL201426A0 (en) | Drug combination and its use in the treatment of muscle loss | |
IL205680A0 (en) | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders | |
HK1134032A1 (en) | New combination for use in the treatment of inflammatory disorders | |
GB2460181B (en) | Depsipeptides and their therapeutic use | |
EP2121785A4 (fr) | Sydnonimines - inhibiteurs de réabsorption de dopamine spécifique et leur utilisation dans le traitement de troubles liés à la dopamine | |
IL208385A0 (en) | Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder | |
EP2313165A4 (fr) | Balle destinée au jeu et/ou à l entraînement | |
GB0710277D0 (en) | Use of antivirals in the treatment of medical disorders | |
GB0718824D0 (en) | Methods of treating lysosomal storage disorders | |
GB0607199D0 (en) | Improved ball valve and valve seat | |
GB2460180B (en) | Depsipeptides and their therapeutic use | |
WO2009046123A3 (fr) | Antagonistes de nlrr-1 et leurs utilisations | |
ZA200904382B (en) | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases |